Rules Based Medicines Launches CardiovascularMAP
Rules Based Medicine (RBM; Austin, TX), a biomarker testing laboratory, announced today the launch of CardiovascularMAP.
Based on RBM’s proprietary Multi-Analyte Profiling (MAP) platform, CardiovascularMAP is designed to advance the development of drugs for cardiovascular disease. Pharmaceutical and biotechnology groups collaborated to design the tool, which combines common biomarkers with additional ones to identify new patterns of disease.
"RBM is providing access to the most comprehensive array of cardiovascular biomarkers ever
assembled in one panel,” said George P. Rodgers, MD, FACC, past chairman of the
American College of Cardiology Board of Governors, in a press release. “Accurate measurement of these
biomarkers clearly has the potential to accelerate CVD research programs."
For more information, click here.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
SOUL Trial Shows Oral Semaglutide Significantly Reduces Cardiovascular Risk in Type 2 Diabetes
April 3rd 2025Phase III SOUL trial shows daily oral semaglutide lowers the risk of major adverse cardiovascular events in patients with type 2 diabetes and atherosclerotic cardiovascular disease or chronic kidney disease, with benefits consistent with injectable semaglutide and other GLP-1 receptor agonists.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
